ASX Share rice
Sat 08 Aug 2020 - 07:11:pm (Sydney)

PTX Share Price

PRESCIENT THERAPEUTICS LIMITEDPTXPharmaceuticals, Biotechnology & Life Sciences

PTX Company Information

Name:

Prescient Therapeutics Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Biotechnology

GIC Sub Industry:

Biotechnology

Address:

100 Albert Road South Melbourne VIC Australia 3205

Phone:

61 3 9692 7222

MD, CEO & Director:

Mr. Yatomi-Clarke Steven Lee

CFO & Company Sec.:

Ms. Melanie Jaye Leydin C.A., B.Bus, CA

Chief Scientific Officer:

Prof. Said M. Sebti Ph.D., M.D.

Chief Medical Officer:

Dr. Terrence G. Chew

Head of Bus. Devel.:

Dr. James D. Winkler

Company Overview:

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of a range of cancers in Australia. The company's lead drug candidate is PTX-200, which is in Phase II clinical trial for negative breast cancer, as well as Phase IB clinical trial in relapsed and refractory ovarian cancer and acute leukemia; and PTX-100, a treatment that has completed Phase I clinical trial for solid tumors. Prescient Therapeutics Limited has a collaboration agreement with Carina Biotech to develop cellular therapies; and a research agreement with the Peter Doherty Institute for Infection and Immunology for SARS-CoV-2 antiviral drugs program. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited is based in South Melbourne, Australia.

PTX Share Price Information

Shares Issued:

394.26M

Market Capitalisation:

$22.47M

Revenue (TTM):

$1.54M

Revenue Per Share (TTM):

$0.01

Earnings per Share:

$-0.016

Profit Margin:

-2.5386

Operating Margin (TTM):

$-2.59

Return On Assets (TTM):

$-0.23

Return On Equity (TTM):

$-0.38

Quarterly Revenue Growth (YOY):

-0.157

Gross Profit(TTM):

$1.65M

Diluted Earnings Per Share (TTM):

$-0.012

PTX CashFlow Statement

CashFlow Date:

2019-06-30

Change To Liabilities:

$144.94K

Net Borrowings:

$-56,046

Net Income:

$-3,797,227

Total Cash From Operating Activities:

$-4,195,468

Depreciation:

$1.34K

Change To Account Receivables:

$-71,671

Sale Purchase Of Stock:

$-699,488

Capital Expenditures:

$0

PTX Income Statement

Income Date:

2019-06-30

Income Before Tax:

$-3,797,227

Net Income:

$-3,797,227

Gross Profit:

$1.65M

Operating Income:

$-5,545,076

Interest Expense:

$3.30K

Total Revenue:

$1.65M

Total Operating Expenses:

$5.55M

PTX Balance Sheet

Balance Sheet Date:

2019-06-30

Intangible Assets:

$3.37M

Total Liabilities:

$685.79K

Total Stockholder Equity:

$14.32M

Other Current Liabilities:

$42.17K

Total Assets:

$15.01M

Common Stock:

$63.93M

Other Current Assets:

$1.63M

Retained Earnings:

$-50,709,181

Other Liabilities:

$17.76K

Cash:

$9.64M

Total Current Liabilities:

$668.03K

Property - Plant & Equipment:

$0.94K

Net Tangible Assets:

$10.95M

Total Current Assets:

$11.64M

Net Receivables:

$1.75M

Short-Term Investments:

$3.37M

Accounts Payable:

$393.15K

Non Currrent Assets (Other):

$3.37M

Short-Term Investments:

$3.37

Non Current Liabilities Total:

$17.76K

PTX Share Price History

PTX News

11 May, 2020
In 2016, Yatomi-Clarke Lee was appointed CEO of Prescient Therapeutics Limited (ASX:PTX). First, this article will...
12 Mar, 2020
Generally speaking long term investing is the way to go. But that doesn't mean long term investors can avoid big...
27 Jan, 2020
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
11 Oct, 2019
Every investor in Prescient Therapeutics Limited (ASX:PTX) should be aware of the most powerful shareholder groups...
23 Aug, 2019
In 2016 Yatomi-Clarke Lee was appointed CEO of Prescient Therapeutics Limited (ASX:PTX). This analysis aims first to...